Johnson & Johnson's Q1 2025 Performance Shines with Strong Portfolio Pipeline and Record-Breaking Sales
Johnson & Johnson, a multinational healthcare company, recently reported its first-quarter results for 2025, showcasing impressive performance across its commercial, R&D, and supply chain capabilities. The company's Chairman and CEO, Joaquin Duato, described the period as a testament to their strength in execution and a reflection of the power of their portfolio pipeline.
Innovative Medicine delivered operational sales growth of 4.2%, despite an 810 basis point headwind from STELARA. Notably, 11 key brands grew double digits during this period. DARZALEX continued to set the standard in multiple myeloma with over 20% quarterly growth and expanded its indication in Europe for patients with newly diagnosed multiple myeloma.
The oncology portfolio also saw significant advancements, including Phase III data presented at ELCC showing that the combination of last cruise and ribbon extended overall survival by more than a year versus the current standard of care in first-line EGFR mutated lung cancer. The European Commission approved subcutaneous redemand in combination with last cruise for this indication, further solidifying the portfolio's growth.
In immunology, TREMFYA's entry into inflammatory bowel disease helped accelerate operational sales growth to 20%. The recent FDA approval of TREMFYA in colon disease has made it more confident than ever that this blockbuster drug will become a $10 billion-plus product and the gold standard for IBD patients.
MEDTECH delivered 4.1% operational sales growth, with strong performance in recently acquired cardiovascular businesses as well as surgical vision and bond closure. The company's portfolio continued to meet deal model expectations, with both announcing important milestones this quarter, including updates to American College of Cardiology and American Heart Association guidelines for their Impella heart pump.
The company has described 2025 as a catalyst year, which is expected to set up accelerated growth through the second half of the decade. Given these strong first-quarter results, it appears Johnson & Johnson is on track to achieve its objectives."
